| Name | Title | Contact Details |
|---|
CatalystRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Philadelphia, PA. To find more information about CatalystRx, please visit www.catalystrx.com
Stratum Health System is a nonprofit, integrated network providing care and support to people facing chronic or advanced illness. The Stratum family of companies helps patients live as comfortably and meaningfully as possible and offers assistance to their families and caregivers along the way. As their illness advances, Stratum offers a layer of medical and emotional support services that provides compassionate care across the continuum.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.
VedeqSA Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.